Онкогематология (Nov 2022)

Role of high-dose chemotherapy with hemopoietic stem cell transplantation in the treatment of multiple myeloma

  • S. V. Minenko,
  • A. Yu. Popov,
  • N. V. Zhukov,
  • O. M. Votyakova,
  • V. V. Ptushkin

DOI
https://doi.org/10.17650/1818-8346-2008-0-4-11-16
Journal volume & issue
Vol. 0, no. 4
pp. 11 – 16

Abstract

Read online

Treatment results in a group of patients with multiple myeloma (n=18) treated with melfalan (200 mg/m2) followed by autologous peripheral blood stem cell transplantation as a second-line therapy are presented. Thirteen patients received one course of high-dose chemotherapy (HDCT), 5 had 2 courses. Before HDCT all treated patients achieved a partial remission (15 patients after 3 courses VAD, 3 patients after 3 courses of VAD and 2 courses of velcade- doxorubicin- prednisolone). The median time to disease progression was 33.1 (range 26—40) months; that of overall survival was 55.4 (range 29— 40) months.

Keywords